These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 17296492)

  • 1. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition.
    Cave M; Deaciuc I; Mendez C; Song Z; Joshi-Barve S; Barve S; McClain C
    J Nutr Biochem; 2007 Mar; 18(3):184-95. PubMed ID: 17296492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nonalcoholic steatohepatitis: pathogenesis and treatment].
    Park SH
    Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment.
    Rahimi RS; Landaverde C
    Nutr Clin Pract; 2013 Feb; 28(1):40-51. PubMed ID: 23286927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic steatohepatitis and the metabolic syndrome.
    Jiang J; Torok N
    Metab Syndr Relat Disord; 2008 Mar; 6(1):1-7. PubMed ID: 18370830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The epidemiology of nonalcoholic fatty liver disease in adults.
    Clark JM
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S5-10. PubMed ID: 16540768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease.
    Angulo P
    Rev Gastroenterol Mex; 2005 Nov; 70 Suppl 3():52-6. PubMed ID: 17471859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment.
    Carter-Kent C; Zein NN; Feldstein AE
    Am J Gastroenterol; 2008 Apr; 103(4):1036-42. PubMed ID: 18177455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC; Berk PD
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease in severely obese subjects.
    Gholam PM; Flancbaum L; Machan JT; Charney DA; Kotler DP
    Am J Gastroenterol; 2007 Feb; 102(2):399-408. PubMed ID: 17311652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of nonalcoholic steatohepatitis (NASH).
    Ma X; Li Z
    Chin J Dig Dis; 2006; 7(1):7-11. PubMed ID: 16412031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric nonalcoholic fatty liver disease.
    Lerret SM; Skelton JA
    Gastroenterol Nurs; 2008; 31(2):115-9. PubMed ID: 18391799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome.
    Boppidi H; Daram SR
    Postgrad Med; 2008 Jul; 120(2):E01-7. PubMed ID: 18654060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease.
    Tilg H; Moschen A
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):159-67. PubMed ID: 20485253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of weight loss on nonalcoholic fatty liver disease.
    Rafiq N; Younossi ZM
    Semin Liver Dis; 2008 Nov; 28(4):427-33. PubMed ID: 18956298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease.
    Hjelkrem MC; Torres DM; Harrison SA
    Minerva Med; 2008 Dec; 99(6):583-93. PubMed ID: 19034256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic disturbances in non-alcoholic fatty liver disease.
    Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
    Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome.
    Targher G; Chonchol M; Miele L; Zoppini G; Pichiri I; Muggeo M
    Semin Thromb Hemost; 2009 Apr; 35(3):277-87. PubMed ID: 19452403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnosis and therapy in NASH].
    Tokushige K
    Rinsho Byori; 2009 Sep; 57(9):848-53. PubMed ID: 19860210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.